Levonorgestrel Stada

Levonorgestrel, the active ingredient in Levonorgestrel Stada, is a progestin presented as an unspecified strength oral tablet for oral use. It is used to prevent pregnancy and to manage certain menstrual disorders in women of reproductive age.

GNH USA supplies Levonorgestrel Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levonorgestrel Stada is a progestin that acts on the hormonal regulation of the menstrual cycle and ovulation. It is employed in several recognized clinical contexts: - Emergency contraception: prevents pregnancy after unprotected intercourse when taken within the approved time window. - Regular hormonal contraception: provides ongoing contraceptive protection for women seeking a reliable oral method. - Management of menstrual disorders: helps regulate menstrual bleeding and can alleviate dysmenorrhea in affected patients.

Levonorgestrel is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient tension‑type headaches. - Breast tenderness: temporary swelling or discomfort. - Irregular bleeding: spotting or breakthrough bleeding. - Abdominal pain: cramping or discomfort. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe allergic reaction: anaphylaxis with rash, swelling, or breathing difficulty. - Liver dysfunction: jaundice or elevated liver enzymes. - Pregnancy: inadvertent use during early pregnancy carries risk. - Ovarian cyst rupture: sudden pelvic pain with possible hemorrhage.

Before prescribing Levonorgestrel Stada, clinicians should consider several safety aspects. - Contraindicated in pregnancy: avoid use in confirmed or suspected pregnancy. - Hepatic impairment: use with caution in patients with liver disease. - Known hypersensitivity: do not administer to individuals with allergy to levonorgestrel or excipients. - Thromboembolic risk: assess history of clotting disorders before use. - Concomitant estrogen therapy: evaluate increased risk of thrombosis. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Levonorgestrel may have clinically relevant interactions that affect its efficacy or safety.

Major Interactions (Avoid): - Rifampicin and other enzyme inducers: markedly reduce contraceptive effectiveness. - Anticonvulsants (phenytoin, carbamazepine, phenobarbital): lower plasma levels, risking breakthrough ovulation. - St. John's wort: herbal inducer that can diminish contraceptive protection.

Moderate Interactions (Monitor Closely): - Ketoconazole and other strong antifungals: may increase levonorgestrel concentrations. - Ritonavir and protease inhibitors: can alter metabolism, requiring monitoring. - Combined estrogen‑containing products: may increase risk of thromboembolic events, necessitating vigilance.